No Data
No Data
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $41
Intellia Therapeutics: Positive Outlook and Buy Rating Amid Promising Data for ATTR-CM Treatment
Earnings Preview: NTLA to Report Financial Results Pre-market on November 07
Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024
Intellia Therapeutics (NTLA): Promising Gene Editing Stock With CRISPR-Cas9 Therapies
Looking Into Intellia Therapeutics's Recent Short Interest
三和巴菲特 : Have you cried today? Baby
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 :
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 : Laughed.
71179109 : Intellia - 20% yesterday